Attached files
file | filename |
---|---|
EX-14.1 - EXHIBIT 14.1 - PIERIS PHARMACEUTICALS, INC. | exhibit141.htm |
EX-32.2 - EXHIBIT 32.2 - PIERIS PHARMACEUTICALS, INC. | exhibit322.htm |
EX-32.1 - EXHIBIT 32.1 - PIERIS PHARMACEUTICALS, INC. | exhibit321.htm |
EX-31.2 - EXHIBIT 31.2 - PIERIS PHARMACEUTICALS, INC. | exhibit312.htm |
EX-31.1 - EXHIBIT 31.1 - PIERIS PHARMACEUTICALS, INC. | exhibit311.htm |
EX-21.1 - EXHIBIT 21.1 - PIERIS PHARMACEUTICALS, INC. | exhibit211.htm |
EX-10.23 - EXHIBIT 10.23 - PIERIS PHARMACEUTICALS, INC. | exhibit1023.htm |
10-K - 10-K - PIERIS PHARMACEUTICALS, INC. | pirs12-31x201710xk.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-8 No. 333-204487) pertaining to the Pieris Pharmaceuticals, Inc. 2014 Employee, Director and Consultant Equity Incentive Plan, |
(2) | Registration Statement (Form S-8 No. 333-209308) pertaining to the Pieris Pharmaceuticals, Inc. 2014 Employee, Director and Consultant Equity Incentive Plan Inducement Stock Option Award for Louis Matis, M.D., |
(3) | Registration Statement (Form S-8 No. 333-213771) pertaining to the Pieris Pharmaceuticals, Inc. 2016 Employee, Director and Consultant Equity Incentive Plan, |
(4) | Registration Statement (Form S-3 No. 333-211844), |
(5) | Registration Statement (Form S-3 No. 333-212439), |
(6) | Registration Statement (Post-Effective Amendment to FORM S-1 ON FORM S-3 No. 333-202123), and |
(7) | Registration Statement (Form S-8 No. 333-221497) pertaining to the Pieris Pharmaceuticals, Inc. 2016 Employee, Director and Consultant Equity Incentive Plan Inducement Stock Option Awards for Claude Knopf, Allan Reine, M.D, and Ingmar Bruns, M.D., Ph.D |
of our report dated March 15, 2018, with respect to the consolidated financial statements of Pieris Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Pieris Pharmaceuticals, Inc. for the year ended December 31, 2017.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 15, 2018